Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

Benzinga Newsdesk www.benzinga.com Negative 49.5%

Neg 49.5% Neu 0% Pos 0%

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.